Literature DB >> 10595524

Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.

T Ishihara1, M Hong, B Zhang, Y Nakagawa, M K Lee, J Q Trojanowski, V M Lee.   

Abstract

Filamentous tau aggregates are hallmarks of tauopathies, e.g., frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC). Since FTDP-17 tau gene mutations alter levels/functions of tau, we overexpressed the smallest human tau isoform in the CNS of transgenic (Tg) mice to model tauopathies. These mice acquired age-dependent CNS pathology similarto FTDP-17 and ALS/PDC, including insoluble, hyperphosphorylated tau and argyrophilic intraneuronal inclusions formed by tau-immunoreactive filaments. Inclusions were present in cortical and brainstem neurons but were most abundant in spinal cord neurons, where they were associated with axon degeneration, diminished microtubules (MTs), and reduced axonal transport in ventral roots, as well as spinal cord gliosis and motor weakness. These Tg mice recapitulate key features of tauopathies and provide models for elucidating mechanisms underlying diverse tauopathies, including Alzheimer's disease (AD).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595524     DOI: 10.1016/s0896-6273(00)81127-7

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  184 in total

Review 1.  Frontotemporal dementia and tauopathy.

Authors:  Y Yoshiyama; V M Lee; J Q Trojanowski
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

Review 3.  Obesity, leptin, and Alzheimer's disease.

Authors:  Edward B Lee
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 4.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 6.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

7.  (+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.

Authors:  Amos B Smith; B Scott Freeze
Journal:  Tetrahedron       Date:  2007-01-07       Impact factor: 2.457

8.  Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model.

Authors:  Meghan N Le; Wonhee Kim; Sangmook Lee; Ann C McKee; Garth F Hall
Journal:  Am J Neurodegener Dis       Date:  2012-11-25

9.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Authors:  Tara L Spires; Jennifer D Orne; Karen SantaCruz; Rose Pitstick; George A Carlson; Karen H Ashe; Bradley T Hyman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 10.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.